A detailed history of Steph & CO transactions in Biogen Inc. stock. As of the latest transaction made, Steph & CO holds 77 shares of BIIB stock, worth $13,381. This represents 0.01% of its overall portfolio holdings.

Number of Shares
77
Previous 52 48.08%
Holding current value
$13,381
Previous $12,000 16.67%
% of portfolio
0.01%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$189.07 - $236.8 $4,726 - $5,920
25 Added 48.08%
77 $14,000
Q2 2024

Jul 30, 2024

BUY
$190.52 - $236.72 $762 - $946
4 Added 8.33%
52 $12,000
Q1 2024

Apr 12, 2024

BUY
$212.02 - $267.71 $10,176 - $12,850
48 New
48 $10,000
Q2 2022

Jul 13, 2022

SELL
$187.54 - $223.02 $15,565 - $18,510
-83 Closed
0 $0
Q4 2021

Jan 24, 2022

BUY
$223.92 - $287.77 $18,585 - $23,884
83 New
83 $20,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Steph & CO Portfolio

Follow Steph & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steph & CO, based on Form 13F filings with the SEC.

News

Stay updated on Steph & CO with notifications on news.